CARGO Therapeutics is a biotechnology company focused on developing next-generation transformational CAR T-cell therapies with the mission of outsmarting cancer to deliver more cures for patients. They are engaged in innovative research and development of therapies targeting B-cell lymphoma and other cancer types, as demonstrated by their pipeline products like Firi-cel (CRG-022) and CRG-023. Their work is characterized by a robust focus on scientific discovery and collaboration within the biotechnology and pharmaceutical sectors.